University of Wisconsin Carbone Cancer Center

Running trials

• Not yet recruiting

  Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer

  NCT07706179· Phase 2· University of Wisconsin, Madison· Source

• Recruiting

  Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy

  NCT07609225· Early phase 1· University of Wisconsin, Madison· Source

• Not yet recruiting

  A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation

  NCT07814417· Phase 2· Eli Lilly and Company· Source

• Recruiting

  Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

  NCT07700979· Phase 3· Akeso· Source

• Recruiting

  Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07562152· Phase 3· Immuneering Corporation· Source

• Recruiting

  A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

  NCT07428616· Phase 2· Exelixis· Source

• Recruiting

  Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

  NCT07326566· Phase 2· Black Diamond Therapeutics, Inc.· Source

• Recruiting

  A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide

  NCT06844383· Phase 2· Prostate Cancer Clinical Trials Consortium· Source

• Recruiting

  Cognitive Impact of Neoadjuvant Chemotherapy for Gynecologic Cancers

  NCT07125209· University of Wisconsin, Madison· Source

• Recruiting

  Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer

  NCT06705686· Phase 1· TechnoGenesys, Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

  NCT07284758· Phase 2· C4 Therapeutics, Inc.· Source

• Recruiting

  Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

  NCT07287917· Phase 1/2· Aminex Therapeutics, Inc.· Source

• Active, not recruiting

  Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

  NCT07109414· Phase 2/3· Novita Pharmaceuticals, Inc.· Source

• Recruiting

  A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

  NCT07213791· Phase 1· Eli Lilly and Company· Source

• Recruiting

  COMPASS Study for Metastatic Castration-resistant Prostate Cancer

  NCT07050433· Duke University· Source

• Active, not recruiting

  A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

  NCT06679985· Phase 2· Coherus Oncology, Inc.· Source

• Active, not recruiting

  Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

  NCT06691984· Phase 3· Amgen· Source

• Recruiting

  A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

  NCT06638307· Phase 1· Stemline Therapeutics, Inc.· Source

• Recruiting

  Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

  NCT06561048· Phase 3· Corvus Pharmaceuticals, Inc.· Source

• Active, not recruiting

  Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

  NCT06538038· PrECOG, LLC.· Source

• Active, not recruiting

  MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

  NCT06586515· Phase 1· Eli Lilly and Company· Source

• Recruiting

  A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

  NCT06246916· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

  NCT06486441· Phase 3· Gilead Sciences· Source

• Recruiting

  MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

  NCT06150417· Phase 2· Case Comprehensive Cancer Center· Source

• Active, not recruiting

  A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

  NCT06388733· Phase 3· Ivy Brain Tumor Center· Source

• Active, not recruiting

  A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

  NCT06157892· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

• Recruiting

  A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

  NCT06234605· Phase 1· HiberCell, Inc.· Source

• Active, not recruiting

  Multicenter Trial of ESK981 in Patients With Select Solid Tumors

  NCT05988918· Phase 2· University of Michigan Rogel Cancer Center· Source

• Active, not recruiting

  Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

  NCT06105021· Phase 1/2· Affini-T Therapeutics, Inc.· Source

• Recruiting

  SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

  NCT06222580· Phase 1· Uma Borate· Source

• Active, not recruiting

  A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

  NCT06143891· Phase 3· Sanofi· Source

• Active, not recruiting

  ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

  NCT05682443· Phase 1/2· OncoC4, Inc.· Source

• Active, not recruiting

  Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

  NCT05899608· Phase 3· Summit Therapeutics· Source

• Recruiting

  KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

  NCT06026410· Phase 1· Kura Oncology, Inc.· Source

• Recruiting

  Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

  NCT05854498· Phase 2· University of Wisconsin, Madison· Source

• Active, not recruiting

  Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

  NCT05610891· Phase 1· Cellectar Biosciences, Inc.· Source

• Recruiting

  SPEARHEAD-3 Pediatric Study

  NCT05642455· Phase 1/2· USWM CT, LLC· Source

• Active, not recruiting

  Study Transplanting Bone Marrow Cells Into Salivary Glands to Treat Dry Mouth Caused by Radiation Therapy

  NCT05820711· Phase 1· University of Wisconsin, Madison· Source

• Recruiting

  MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

  NCT05655312· Phase 1/2· Perspective Therapeutics· Source

• Recruiting

  FOG-001 in Locally Advanced or Metastatic Solid Tumors

  NCT05919264· Phase 1/2· Parabilis Medicines, Inc.· Source

• Recruiting

  SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

  NCT05568680· Phase 1· Verismo Therapeutics· Source

• Active, not recruiting

  Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

  NCT05633602· Phase 3· SWOG Cancer Research Network· Source

• Recruiting

  Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

  NCT05101551· Phase 1· Norman J. Lacayo· Source

• Active, not recruiting

  A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

  NCT05551936· Phase 1/2· Vaishalee Kenkre· Source

• Active, not recruiting

  Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

  NCT05563220· Phase 1/2· Stemline Therapeutics, Inc.· Source

• Recruiting

  Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

  NCT05798897· Phase 1· Marker Therapeutics, Inc.· Source

• Active, not recruiting

  To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

  NCT05468489· Phase 2· Shanghai Henlius Biotech· Source

• Active, not recruiting

  STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

  NCT05455658· Phase 2· University of Washington· Source

• Recruiting

  Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

  NCT05519449· Phase 1· Janux Therapeutics· Source

• Active, not recruiting

  Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

  NCT05230810· Phase 1/2· Criterium, Inc.· Source

Showing 50 of 92.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer10 recruiting
• Colorectal cancer6 recruiting
• Liver and biliary tract cancer5 recruiting
• Childhood cancers4 recruiting
• Melanoma4 recruiting
• Metastatic breast cancer4 recruiting
• Ovarian cancer4 recruiting
• Pancreatic cancer4 recruiting
• Acute myeloid leukaemia3 recruiting
• Gastric and oesophageal cancer3 recruiting
• Lung cancer3 recruiting
• Endometrial cancer2 recruiting
• Hodgkin lymphoma2 recruiting
• Kidney cancer2 recruiting
• Multiple myeloma2 recruiting
• Neuroblastoma2 recruiting
• Sarcoma2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Brain metastases1 recruiting
• Glioblastoma1 recruiting
• Head and neck cancer1 recruiting
• Meningioma1 recruiting
• Mesothelioma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Terminated

  Mental Health App for Cancer Survivors Study

  NCT06472726· University of Wisconsin, Madison· Source

• Completed

  Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma

  NCT06308913· Early phase 1· University of Wisconsin, Madison· Source

• Completed

  Tobacco Treatment Comparison for Cancer Care

  NCT06218823· Phase 4· University of Wisconsin, Madison· Source

• Terminated

  A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.

  NCT05917470· Phase 1/2· Oncternal Therapeutics, Inc· Source

• Terminated

  Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

  NCT05980416· Phase 1· Elevation Oncology· Source

• Completed

  TRAQinform Assessment of Immunotherapy Response

  NCT05819255· AIQ Solutions· Source

• Recruiting

  IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

  NCT05742607· Phase 2· Innate Pharma· Source

• Completed

  Pilot Study of Imatinib Cetuximab Combo for H & N Cancer

  NCT05816785· Early phase 1· University of Wisconsin, Madison· Source

• Recruiting

  Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

  NCT05283226· Phase 2· NATCO Pharma Ltd.· Source

• Completed

  A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

  NCT05360680· Phase 1· Cue Biopharma· Source

• Terminated

  A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

  NCT05242822· Phase 1· Kinnate Biopharma· Source

• Completed

  Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

  NCT05103358· Phase 2· Aadi Bioscience, Inc.· Source

• Completed

  Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

  NCT04997902· Phase 1/2· Kura Oncology, Inc.· Source

• Completed

  A Study of SEA-CD40 Given With Other Drugs in Cancers

  NCT04993677· Phase 2· Seagen Inc.· Source

• Terminated

  Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

  NCT04221438· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Terminated

  Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

  NCT04203160· Phase 1/2· University of Michigan Rogel Cancer Center· Source

• Terminated

  A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

  NCT04254107· Phase 1· Seagen Inc.· Source

• Completed

  A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

  NCT04199104· Phase 3· Merck Sharp & Dohme LLC· Source

• Terminated

  IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma

  NCT03958383· Phase 1/2· University of Wisconsin, Madison· Source

• Completed

  CLR 131 Combined With Radiation for Head and Neck Cancer

  NCT04105543· Phase 1· University of Wisconsin, Madison· Source

• Terminated

  A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

  NCT04032704· Phase 2· Seagen Inc.· Source

• Completed

  Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

  NCT03778931· Phase 3· Stemline Therapeutics, Inc.· Source

• Completed

  Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

  NCT03797326· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

  NCT03516981· Phase 2· Merck Sharp & Dohme LLC· Source

• Terminated

  Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

  NCT03393741· University of Wisconsin, Madison· Source

• Completed

  Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

  NCT03142334· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer

  NCT03232164· Early phase 1· University of Wisconsin, Madison· Source

• Completed

  Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

  NCT02973789· Phase 3· NovoCure GmbH· Source

• Completed

  Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer

  NCT02566772· Phase 1· Taiho Oncology, Inc.· Source

• Completed

  Stereotactic Body Radiation Therapy With Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients With Prostate Cancer

  NCT02470897· University of Wisconsin, Madison· Source

• Completed

  Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

  NCT01979536· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

  NCT01553149· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

  NCT01236560· Phase 2/3· National Cancer Institute (NCI)· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Mantle cell lymphoma4 works · 2 trials